Landscape of phase 1 clinical trials for minors with cancer in the United States-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Landscape of phase 1 clinical trials for minors with cancer in the United States

Published:2020-09-04 Issue:11 Volume:67 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Nader Jaclynne H.¹^ORCID,Neel Dylan V.²,Shulman David S.²³^ORCID,Ma Clement²³,Bourgeois Florence²⁴,DuBois Steven G.²³^ORCID

Affiliation:

1. University of Massachusetts Medical School Worcester Massachusetts

2. Harvard Medical School Boston Massachusetts

3. Dana‐Farber/Boston Children's Cancer and Blood Disorders Center Boston Massachusetts

4. Pediatric Therapeutics and Regulatory Science Initiative Computational Health Informatics Program Boston Children's Hospital Boston Massachusetts

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28694

Reference22 articles.

1. Cancer statistics, 2018

2. Aging and Risk of Severe, Disabling, Life-Threatening, and Fatal Events in the Childhood Cancer Survivor Study

3. Innovations for phase I dose-finding designs in pediatric oncology clinical trials

4. Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective

5. Timing of first-in-child trials of FDA-approved oncology drugs

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Absolute neutrophil count clinical trial eligibility criteria for pediatric oncology phase I and phase I/II trials by sponsorship;Pediatric Blood & Cancer;2024-02-26

2. Landscape of Phase II Trials in Alzheimer’s Disease;Journal of Alzheimer's Disease;2023-11-07

3. Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents;The Lancet Child & Adolescent Health;2023-03

4. Changing incentives to ACCELERATE drug development for paediatric cancer;Cancer Medicine;2023-01-16

5. Two‐stage subgroup‐specific time‐to‐event (2S‐Sub‐TITE): An adaptive two‐stage time‐to‐toxicity design for subgroup‐specific dose finding in phase I oncology trials;Pharmaceutical Statistics;2022-05-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3